Ticker Details
X4 Pharmaceuticals Inc Arsanis Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of monoclonal antibodies for the targeted immunotherapy of serious infections.
IPO Date:	May 13, 2022
Sector:	Healthcare
Industry:	Biotech
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.08 | 7.43%
Avg Daily Range (30 D):	$0.01 | 12.24%
Avg Daily Range (90 D):	$0.01 | 12.35%

Institutional Daily Volume
Avg Daily Volume:	3.04M
Avg Daily Volume (30 D):	.22M
Avg Daily Volume (90 D):	.27M

Trade Size
Avg Trade Size (Sh.):	537
Avg Trade Size (Sh.) (30 D):	5,495
Avg Trade Size (Sh.) (90 D):	3,457

Institutional Trades
Total Institutional Trades:	10
Avg Institutional Trade:	$.93M
Avg Institutional Trade (30 D):	$2.54M
Avg Institutional Trade (90 D):	$2.54M
Avg Institutional Trade Volume:	.02M
Avg Institutional Trades (Per Day):	5

Market Closing Trades
Avg Closing Trade:	$.53M
Avg Closing Trade (30 D):	$M
Avg Closing Trade (90 D):	$M
Avg Closing Volume:	14.29K

News

Apr 10, 2026 @ 6:06 AM Why Actelis Networks Stock (ASNS) Crashed 33% Over... Source: Tanya Rawat

Mar 24, 2026 @ 1:10 PM Actelis Networks Announces Binding Term Sheet to A... Source: Globe Newswire

Mar 12, 2026 @ 8:24 AM Actelis Networks Declines Nearly 10% Following 48%... Source: Mohd Haider

Mar 4, 2026 @ 3:14 AM Actelis Networks (ASNS) Surges Over 55% After Hour... Source: Mohd Haider

Dec 18, 2025 @ 1:01 AM Actelis Networks Announces Pricing of $5 Million P... Source: Actelis Networks, Inc.

Financials
	TTM	TTM	Q1 2026
Basic EPS		$-5.46	$-.16
Diluted EPS		$-5.46	$-.16
Revenue		$4.1M	$.96M
Gross Profit		$1.48M	$.24M
Net Income / Loss		$-8.35M	$-2.46M
Operating Income / Loss		$-7.05M	$-1.86M
Cost of Revenue		$2.62M	$.72M
Net Cash Flow		$5.05M	$3.18M
PE Ratio

Splits
Nov 18, 2025	1:10
Apr 19, 2023	1:10
Mar 14, 2019	1:6